Similarly, in a similar analysis of clear cell renal cancer patients' response to immune checkpoint therapy, no significant difference in CD3E-PD-1 correlation was found between responders and nonresponders [29]. This evidence concerns the gene CD3E and clear cell renal carcinoma.